Apresin

Quick links to important sections

Apresin

Method of action: Antidepressant, Psychoanaleptics

Treatment option: Depression

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Apresin

Quick Facts

Property Description
Active ingredient Nortriptyline Hydrochloride
Form Oral Capsule, Tablet, Solution
Pharmacological class Tricyclic Antidepressant (TCA)
Common use Modulating mood and managing persistent nerve discomfort
Origin Synthetic; active metabolite of Amitriptyline

What Type of Medicine is Apresin (Nortriptyline)?

Apresin is a brand name for the prescription medication containing the single active compound, Nortriptyline Hydrochloride. It is unequivocally classified as a Tricyclic Antidepressant (TCA), specifically belonging to the secondary amine subclass. This pharmacological class represents an established generation of compounds clinically recognized for addressing chemical imbalances within the central nervous system. Nortriptyline is a synthetic compound derived as the active metabolite of the older TCA, Amitriptyline. The drug is formulated for oral administration and is typically supplied in capsules, tablets, or liquid solutions, differentiating it from topically applied or injectable medications.

Apresin’s General Purpose and Mechanism Overview

The general purpose of Apresin is to help restore neurochemical balance, thereby alleviating symptoms associated with persistent low mood or emotional disturbance. The medication achieves this through neurotransmitter modulation, primarily by inhibiting the reabsorption (reuptake) of two key signaling chemicals in the brain: Norepinephrine and, to a lesser extent, Serotonin. This core action helps to stabilize and sustain the presence of these crucial neurotransmitters. Furthermore, its influence on various nerve pathways provides the general benefit of helping to manage specific types of chronic, nerve-related discomfort that is often refractory to standard interventions.

Regulatory References

  1. Nortriptyline Mechanism of Action (NIH)

What side effects are possible with Apresin?

Possible side effects and safety information

This section describes the officially documented adverse reactions and safety characteristics of Apresin (Nortriptyline) as classified and published by government regulatory authorities.

Official Adverse Reaction Scope

The safety profile is characterized by effects categorized by frequency and physiological system. Very Common (ge 1/10) adverse reactions documented in regulatory labels include tremor, dizziness, dry mouth, constipation, palpitations, and tachycardia. Common (ge 1/100 to < 1/10) effects involve confusional state, reduced libido, and certain ECG abnormalities.

Adverse effects are documented across several System-Organ Classes, notably the Nervous System (e.g., headache, ataxia), Cardiac System (e.g., arrhythmia, heart block), and Gastrointestinal System (e.g., dry mouth, nausea).

Clinically Significant Safety Information

Regulatory documents list several serious adverse reactions. These include major cardiovascular events such as myocardial infarction and stroke. Rare but severe hematological reactions like agranulocytosis and potentially life-threatening conditions like Serotonin Syndrome are also documented. The official safety labeling includes a documented risk of suicidal thoughts and behaviour, particularly in adolescents, young adults, and children.

Population and Time-Related Safety

Older adults are particularly susceptible to certain adverse reactions, including confusion and postural hypotension. Safety information notes that the risk of suicidal thoughts and actions is concentrated around the initial stages of treatment and following dose changes.

Safety-Related Restrictions

Official labels define specific limitations for use. Apresin is contraindicated during the acute recovery period immediately following a Myocardial Infarction. Furthermore, the medicine should not be used in individuals with pre-existing heart block or certain other cardiac arrhythmias.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Apresin (Nortriptyline), a tricyclic antidepressant (TCA), is considered a life-threatening medical emergency and requires immediate action as documented in regulatory guidelines. The official prescribing information states that an overdose can be fatal and is primarily characterized by severe effects on the cardiovascular and central nervous systems.

Documented Overdose Manifestations

System Documented Signs and Symptoms
Cardiovascular Cardiac arrhythmias, severe hypotension, shock, and rapid heart rate.
Central Nervous System Confusion, agitation, seizures, coma, and respiratory depression.
Anticholinergic Dilated pupils, blurred vision, dry mouth, and urinary retention.

Emergency Actions Mandated by Regulators

Immediate medical attention must be sought if an overdose is suspected. Officially documented life-saving procedures include securing the airway and initiating continuous cardiac monitoring, specifically watching for QRS segment widening on the electrocardiogram (ECG), which indicates severe toxicity. Gastrointestinal decontamination using procedures such as gastric lavage and activated charcoal is often described in regulatory protocols.

No specific antidote is known for Nortriptyline overdose. Management focuses exclusively on supportive and symptomatic treatment to manage the life-threatening complications.

Therapeutic Uses of Apresin

What Apresin Treats: Main Uses and Benefits

Apresin is commonly used to help manage symptoms related to a few distinct clinical areas. It is applied in addressing conditions such as Major Depressive Disorder (MDD), certain types of chronic nerve pain, and easing the frequency of migraine episodes. This medication is relevant for supporting efforts toward emotional stabilization in MDD, including persistent low mood and anhedonia, and may assist with supportive relief for debilitating nerve discomfort characterized by burning or shooting sensations.

The therapeutic approach is focused on symptom relief, especially in contexts where symptoms create noticeable functional strain. This approach may support the patient during difficult episodes by helping to ease distress and may contribute to improved day-to-day comfort. Apresin may also be used to ease co-morbid symptoms like insomnia and fatigue, and may be part of symptomatic management in programs for smoking cessation.


Quick Fact: Relief for Persistent Discomfort
Primary Focus: Role in addressing symptoms of chronic, persistent, non-mechanical pain signals.
Emotional Support: Contributes to efforts toward emotional stability in Major Depressive Disorder (MDD).
Auxiliary Role: Relevant for easing the frequency of migraine episodes and supporting sleep.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Apresin (nortriptyline) eligibility is strictly defined by regulatory criteria regarding age, pre-existing health conditions, and drug interactions.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults (18 years and older). Patients with renal failure may be given usual doses as the drug’s processing is unaffected [HPRA SmPC].
Populations for whom use is contraindicated Patients using, or who have used within the last 14 days, a psychiatric MAO Inhibitor; concurrent use with linezolid or intravenous methylene blue is also prohibited [FDA Label]. Use is contraindicated during the acute recovery period following myocardial infarction [FDA Label].
Age-related eligibility rules Pediatric (Under 18): Use is not recommended; safety and effectiveness are not established [HPRA SmPC]. Geriatric (65 and Over): Lower than usual dosages are recommended due to increased sensitivity and potential for adverse effects [FDA Label]. Young Adults (18–24): Close monitoring is required due to an officially documented increased risk of suicidal ideation and behavior [FDA Label].
Condition-specific eligibility rules Use requires close supervision in patients with pre-existing cardiovascular disease, a history of seizures, or conditions like glaucoma or urinary retention [FDA Label]. Careful dosing is necessary for patients with reduced hepatic function [HPRA SmPC].

Eligibility Classifications

The labels state that safe use during pregnancy and lactation has not been established, requiring a benefit-versus-risk assessment. The entire population scope is restricted by absolute prohibitions and conditional requirements based on physiological status.

What should I know about interactions with other medicines?

Apresin Interactions with other medicines and products

The official interaction profile for Apresin (Nortriptyline) is defined by strict co-administration restrictions and documented metabolic pathways. Factual statements regarding interactions are based solely on authoritative government regulatory sources.

Mandatory Co-administration Restrictions

Apresin is formally classified as contraindicated for concurrent use with Monoamine Oxidase Inhibitors (MAOIs), including specific agents such as Linezolid and Intravenous Methylene Blue. This prohibition is due to the documented risk of severe pharmacodynamic outcomes. Regulatory documentation requires a mandatory separation period of at least two weeks (14 days) when switching between an irreversible MAOI and Apresin. Additionally, use is restricted during the acute recovery period following myocardial infarction.

Pharmacokinetic and Pharmacodynamic Interactions

The medicine is primarily metabolized through the enzyme Cytochrome P450 2D6 (CYP2D6). Co-administration with known CYP2D6 inhibitors (e.g., cimetidine, quinidine, certain other antidepressants) is a documented pharmacokinetic interaction that increases the plasma concentration of Nortriptyline. This reduced clearance is associated with potential toxicity. Individuals identified as CYP2D6 Poor Metabolizers also have higher expected plasma levels. Apresin carries a documented risk of pharmacodynamic potentiation when combined with other Central Nervous System (CNS) depressants. Excessive consumption of alcohol (ethanol) may have an additive effect, and the official label notes that Apresin may block the antihypertensive action of Guanethidine.

Mechanism of Action

Apresin is a brand name for the direct-acting peripheral vasodilator, hydralazine, which primarily targets the resistance arterioles within the systemic circulation. Its core mechanism is the direct relaxation of vascular smooth muscle cells, leading to arteriolar vasodilation. This effect is mediated by the inhibition of inositol trisphosphate ( IP3)-induced calcium ( Ca^2+) release from the sarcoplasmic reticulum. By preventing the intracellular Ca^2+ spike, the drug interferes with Ca^2+-dependent myosin light chain phosphorylation, which is essential for the actin-myosin cross-bridge cycling and muscle contraction. Downstream, this reduction in arteriolar muscle tone results in a decrease in total peripheral resistance. This systemic-level physiological consequence modulates the arterial pressure within the vasculature. The resulting decrease in arterial pressure triggers a baroreceptor reflex, leading to a compensatory increase in sympathetic nervous system outflow, which consequently augments heart rate and cardiac contractility.

Dosage and Administration Information

Apresin (Nortriptyline) is intended solely for oral administration and is available in capsule, tablet, and liquid solution forms. The primary schedule for adults permits two main patterns: the total daily dose may be administered in divided doses throughout the day or taken as a single dose, usually recommended for administration at bedtime.

Treatment follows a titration principle, beginning at a low initial dose—such as 25 mg daily for adults—which is then gradually increased based on the prescribed regimen to reach the usual maintenance range of 75 mg to 100 mg daily. Dosage for all patients is subject to a maximum recommended limit of 150 mg per day.

Usage instructions specify that the medicine can be taken with or without food. Lower initial and maintenance dose limits are mandated for specific groups: Older adults and adolescents are typically prescribed a range between 30 mg and 50 mg daily. Due to the drug’s extensive metabolism, specific caution regarding lower doses is advised for patients with hepatic impairment. The duration of therapy is considered long-term, often extending for several months after a response is observed. When therapy is discontinued, the dose must be gradually reduced over a period of time to avoid abrupt cessation.

Recent Clinical Evidence

Apresin: Recent Clinical Evidence

The evidence base for Apresin (Nortriptyline) is primarily derived from randomized controlled trials (RCTs), systematic reviews, and meta-analyses. These studies contribute to understanding how the compound was evaluated for its intended uses and for contextualizing the findings documented by regulators. Research provides context but not individual predictions.


Evidence for Use in Major Depressive Disorder

Apresin was studied for its use in addressing symptoms related to Major Depressive Disorder (MDD). The majority of the evidence comes from short-term RCTs and subsequent pooled analyses focused on adult patients. Studies reported how symptoms evolved, highlighting changes measured during the study period. Findings from longer-term observational settings described patterns where continued use was associated with symptom recurrence being monitored at lower rates. However, follow-up durations were limited in many initial RCTs.


Evidence for Use in Chronic Nerve Pain

Research explored Apresin for its potential role in managing chronic nerve-related physical discomfort. The evidence base consists of various RCTs and systematic reviews. Studies reported that the measured pain intensity was numerically lower in the monitored treatment groups compared to placebo across certain conditions. However, the findings were mixed, and evidence quality varies across studies due to the modest sample sizes and methodological limitations in older research. The certainty remains low for many specific types of chronic nerve pain.


Evidence in Specific Populations and Research Gaps

The initial studies focused primarily on general adult populations. Specialized analyses were conducted in adults aged 65 and older for MDD, where findings described patterns observed in these studies. A primary limitation across several indications is that the follow-up durations were limited, meaning the long-term effects are not fully established. For migraine and pain, comparative evidence against newer treatment classes is often lacking, and data for certain groups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Apresin (FAQ)

Q: Does Apresin have any common side effects people talk about online?

A: Regulatory documents list specific adverse reactions by how often they were reported in clinical studies. Officially documented Very Common effects include tremor, dizziness, dry mouth, and constipation. These classifications are based on observed frequencies recorded in the official safety profile.

Q: Will Apresin interact with herbal supplements like St. John's Wort?

A: Official product information notes that the use of Apresin with St. John's Wort has a documented risk of causing a serious condition known as Serotonin Syndrome. This outcome is related to excessive activity of the chemical serotonin in the body and is a specific risk mentioned in the regulatory documents.

Q: Is Apresin safe for older adults or seniors to use?

A: Official documentation indicates that Apresin can be used by older adults (aged 65 and over), but lower than usual dosages are typically recommended. This adjustment reflects regulatory caution due to their increased sensitivity and potential for specific adverse reactions, such as confusion and a drop in blood pressure upon standing (postural hypotension).

Q: Is it normal to feel slightly dizzy when starting Apresin?

A: Dizziness is listed as a Very Common adverse reaction in the official safety profile. Effects like dizziness and drowsiness may be more pronounced when a person first begins taking the medication or following a change in dosage.

Q: Are headaches a common experience when first starting Apresin?

A: Headache is listed among the documented adverse reactions related to the Nervous System. Official information advises that any changes in side effect frequency or intensity are monitored closely, according to safety information.

Q: What if I'm taking multiple prescriptions; is Apresin still suitable?

A: Suitability is defined by documented warnings and contraindications related to co-administration. Apresin must not be used concurrently with certain medications, such as MAOIs. Official documentation also advises caution with drugs that affect the CYP2D6 enzyme or act as Central Nervous System depressants. Use requires a review of the patient's full prescription history to determine suitability.

Q: Can people with liver disease use Apresin?

A: Official eligibility rules indicate that the use of Apresin for patients with reduced hepatic function (liver function) requires careful attention to dosing adjustments. This condition is documented as requiring careful dosing adjustments.

Q: Do I need to change my diet while taking Apresin?

A: Official documents only specify a strong warning against the excessive consumption of alcohol (ethanol) while using the medicine, noting its potential for a potentiating effect. No mandatory changes to the general diet are noted in the regulatory information.

Q: Does Apresin affect sleep patterns?

A: Officially documented adverse reactions that may influence sleep patterns include both insomnia (trouble sleeping) and drowsiness (feeling tired). These effects are listed in the medicine’s safety profile.

Q: Are there any long-term effects of using Apresin that I should know about?

A: The official research summary notes a primary limitation that follow-up durations were limited in many initial studies. This indicates that information on effects spanning beyond the study periods is not fully established within that initial evidence base.

Q: Can Apresin cause problems with my stomach or digestion?

A: The official safety profile lists several gastrointestinal effects among its documented adverse reactions. These include constipation (Very Common), nausea, vomiting, diarrhea, and stomach pain.

Q: How long do most people take Apresin for?

A: Official prescribing information describes the expected duration of therapy as long-term, often continuing for several months after an individual begins to show an observed response to the medication.

Q: Does Apresin require special monitoring, like blood tests?

A: Regulatory labels require patients to be monitored closely for clinical worsening or unusual changes in behavior, particularly during the first few months and following dose changes. Close supervision is also described as being required for patients with pre-existing cardiovascular conditions, according to the label.

Q: Does Apresin affect your ability to drive or operate machinery?

A: Official warnings state that the medicine may impair the mental and/or physical abilities required to perform hazardous tasks, such as driving a car or operating machinery, and official regulatory labeling contains warnings regarding these tasks.

Q: Why do official documents mention potential interactions with alcohol?

A: The warning against excessive alcohol consumption is documented because it may have a potentiating effect, meaning it increases the overall impact of the medicine. This is associated with an elevated risk of overdosage and may lead to increased suicidal attempts.

Q: Are there any known issues with Apresin and mental health conditions?

A: Regulatory documents note that use in patients with schizophrenia may exacerbate the condition. Furthermore, in those with manic-depressive illness, Apresin may activate the manic phase, necessitating careful observation.

Q: Is the benefit of Apresin supported by strong evidence?

A: The evidence supporting the use of the medicine is primarily derived from randomized controlled trials (RCTs) and systematic reviews. However, official documentation also notes that evidence quality varies and certainty remains low for some specific uses, such as chronic nerve pain.

Q: Can Apresin cause changes in my blood pressure?

A: Adverse reactions include effects on the cardiovascular system, specifically documented as postural hypotension (a drop in blood pressure upon standing) and general fluctuations in blood pressure across various populations.

Q: What are the signs of a severe reaction to Apresin?

A: Official documentation of severe adverse reactions and toxicity includes signs such as uneven heartbeats, extreme drowsiness, agitation, confusion, seizures, and muscle stiffness. These documented signs indicate the need for prompt evaluation.

Q: Does the time of day matter when taking Apresin?

A: Official prescribing information states that the total daily dose can be taken as a single dose. This single daily dose is usually recommended for administration at bedtime, often to manage the potential for sedation or drowsiness.

Q: Is Apresin associated with any weight changes?

A: Official adverse reaction documentation lists changes in weight, including both weight gain or weight loss, as a possible side effect of the medicine.

Q: Are there different strengths of Apresin available?

A: According to the FDA Prescribing Information, the medicine is officially available in oral capsule strengths of 10 mg, 25 mg, 50 mg, and 75 mg. An oral solution formulation is also available.

Q: Does Apresin work for all types of [Condition Apresin treats]? (e.g., severe/mild)

A: Regulatory-reviewed research evidence describes findings for certain conditions, such as major depressive disorder and chronic nerve pain. However, documentation specifically notes that certainty remains low for many specific types of chronic nerve pain due to study limitations.

Q: Are there any warnings about using Apresin before surgery?

A: Official warnings are documented regarding the potential for interaction with anesthesia and the risk of cardiac arrhythmia during procedures. Regulatory documents recommend the discontinuation of therapy before elective surgery.

Q: What clinical trials led to Apresin's approval?

A: The regulatory evidence base is publicly summarized as being primarily derived from randomized controlled trials (RCTs) and systematic reviews. These studies provided the data that contributed to the compound's initial assessment and approval.

Q: How long does Apresin stay in the body?

A: Official pharmacokinetic information indicates that the medicine is primarily metabolized and eliminated from the body through the liver's Cytochrome P450 2D6 (CYP2D6) pathway. Genetic variations in this enzyme system are known to affect how quickly the medicine is cleared.

Q: Is Apresin a habit-forming drug?

A: Official documentation clarifies that while abruptly stopping the medicine can produce symptoms like dizziness and nausea, these withdrawal symptoms are not considered indicative of addiction.

Q: Can I stop taking Apresin suddenly?

A: Regulatory documents explicitly state that when therapy is discontinued, the dose must be gradually reduced over a period of time. This practice of gradual reduction is necessary to avoid the withdrawal symptoms that may result from abrupt cessation.

Q: Is Apresin a controlled substance?

A: Apresin is classified as a Tricyclic Antidepressant (TCA). This is a class of prescription-only medication whose availability is regulated by health authorities.

How should Apresin be stored and disposed of?

How to Store and Dispose of Apresin (Nortriptyline)

The storage and handling of Apresin (nortriptyline hydrochloride) must adhere strictly to the conditions specified on the official product labeling to maintain stability and ensure safety.

Requirement Official Condition
Temperature Controlled Room Temperature: 20 C to 25 C (68 F to 77 F).
Protection Keep from freezing and protect from light and moisture.
Container Store in a tightly closed container.
Child Safety Must be kept out of the reach of children.

Any unused or expired Apresin must not be kept. Regulatory guidelines advise consulting a healthcare professional or pharmacist for specific disposal instructions. For general household disposal of non-flushable medicines, it is recommended to mix the product with an undesirable substance, seal it, and discard it in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Apresin found in:

A-Z Index: